2014-01-14 10:22 PM
SAN ANTONIO--(BUSINESS WIRE)--Jan 14, 2014--Kinetic Concepts, Inc. announced today the publication of a supplement, recently released in the International Wound Journal (IWJ), which outlines current wound care challenges and practices and presents evidence and clinical experience related to use of V.A.C. VeraFlo? Instillation Therapy (NPWTi) for cleansing and treatment of contaminated or complex wounds. The supplement is based on presentations from the 2012 and 2013 International Surgical Wound Forums, which featured expert research on modern wound treatment challenges and techniques.
"This dedicated supplement significantly adds to the growing body of evidence and guidelines supporting V.A.C. VeraFlo? Therapy and further illustrates how V.A.C. VeraFlo? Therapy is changing clinicians' approach to treating wounds," said Dr. Ron Silverman, Chief Medical Officer, KCI.
The IWJ supplement includes a prologue from chair and guest editor, Christian Willy, MD, PhD, Professor, Military Hospital, Berlin, Germany, as well as articles from over a dozen globally recognized wound care leaders. Topics include surgical site infections, instillation in diabetic foot wounds and instillation with various topical solutions. The supplement also addresses various clinical aspects of wound infections, including epidemiology, microbiology, prevention and treatment.
"One of the most pressing and consistent concerns clinicians must address when treating acute and chronic wounds is hospital-acquired infections, which is why best practice guidelines and clinical research on proper techniques are so vital," said Dr. Willy. "For the less experienced user, this compilation should serve as the most recent introduction to the subject matter, whereas the seasoned practitioner will find of interest the detailed overview of the scientific and theoretical background knowledge that has been published to date."
Publication of the IWJ supplement has been supported by an educational grant from KCI Europe Holding BV. It is available in print or by accessing http://onlinelibrary.wiley.com/doi/10.1111/iwj.2013.10.issue-s1/issuetoc.
V.A.C. VeraFlo? Instillation Therapy combines the benefits of V.A.C. R Therapy with automated topical solution distribution and removal. To learn more about KCI and V.A.C. VeraFlo? Therapy, visit www.KCI1.com.
Kinetic Concepts Inc. (KCI) is a leading global medical technology company devoted to understanding, developing and commercializing innovative, high-technology transformational healing solutions for customers and patients in more than 65 countries around the world. KCI, along with LifeCell Corporation and Systagenix Wound Management, form one globally diversified wound care, biologics and regenerative medicine company, committed to advancing the science of medicine to reduce complications, speed healing and improve patient lives. Headquartered in San Antonio, Texas, the company is a leader in the medical technology industry with the most comprehensive offering of best-in-class surgical and chronic wound therapies. Additional information about KCI and its products is available at www.KCI1.com.
CONTACT: KCI Corporate Communications
Mike Barger, +1-210-255-6824
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY MEDICAL DEVICES
SOURCE: Kinetic Concepts Inc.
Copyright Business Wire 2014
PUB: 01/14/2014 09:00 AM/DISC: 01/14/2014 09:00 AM